Products for Research Use Only

Ibiglustat

CAT: 0804-HY-16743-01Size: 2 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16743-01Size:2 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
CAS Number
1401090-53-6
Product Name Alternative
Venglustat; SAR402671; GZ402671
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Glucosylceramide Synthase (GCS)
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/Ibiglustat.html
Purity
99.76
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C
Molecular Formula
C20H24FN3O2S
Molecular Weight
389.49
Precautions
H302, H315, H319, H335
References & Citations
[1]Stojkovska I, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease. Cell Tissue Res. 2018;373 (1) :51-60. doi:10.1007/s00441-017-2704-y|[2]Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37 (6) :1013-22.|[3]Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11 (1) :20945. Published 2021 Oct 22. |[4]Peterschmitt MJ, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021;10 (1) :86-98.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3